Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 162 member A (FAM162A) is a mitochondrial protein that promotes intrinsic apoptosis, particularly in response to hypoxic stress. FAM162A interacts with hypoxia-inducible factor-1α (HIF-1α) and plays a critical role in the regulation of apoptosis by triggering mitochondrial release of cytochrome c, activation of caspase-9/3, and, in neuronal cells, promoting the release of AIFM1 for caspase-independent cell death. It is implicated in pathological processes associated with hypoxia, such as cerebral ischemia, myocardial infarction, and various cancers, and may serve as a diagnostic marker for early-stage cervical cancer due to its expression pattern. The protein contains two transmembrane domains required for mitochondrial localization and apoptotic function. There are currently no approved drugs or direct chemical inhibitors/activators known to target FAM162A[1][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 162 member A (FAM162A).